Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Conference Call Details

Date:

Wednesday, October 30, 2024

Time:

5:00 p.m. U.S. EST

Webcast:

https://ir.bauschhealth.com/events-and-presentations

A replay of the conference call will be available on the investor relations website.

To participate in the live Q&A session, please register using this link to receive an email confirming your registration with further details.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.

###

Investor Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll-free)

Media Contact:
Katie Savastano
corporate.communications@bauschhealth.com
(908) 541-3785

SOURCE: Bausch Health Companies Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024

Financial HighlightsDirect MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine…

1 hour ago

Cantargia’s Strong Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab Published in Clinical Cancer Research

LUND, SWEDEN / ACCESSWIRE / October 10, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq…

1 hour ago

CZI, State and City Leaders Launch Chan Zuckerberg Biohub New York

CZ Biohub New York is catalyzing collaboration among scientists in the New York area from…

4 hours ago

Top Young Innovator Announces Dallas-Based Hisham Ahmad as America’s “Top Young Innovator 2024”

DiscoverSTEM Celebrates Innovation with Award-Winning Solutions from Youth Innovators Across the USA and UAE.Dallas, Texas--(Newsfile…

5 hours ago

Formula Wellness Appoints Michael Bennett as Chief Executive Officer, Paving the Way for Expansion and Innovation

DALLAS, TX / ACCESSWIRE / October 9, 2024 / Formula Wellness, a leading innovator in…

7 hours ago